- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of December 6
Here are the top 5 biosimilar articles for the week of December 6, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of December 6, 2021.
Number 5: The arrival of biosimilars for filgrastim and pegfiltrastim coincided with higher use of granulocyte colony-stimulating factor (G-CSF) for prophylaxis against febrile neutropenia, but many high-risk patients still do not receive the treatment.
Number 4: In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey ordered Samsung Bioepis to delay marketing Eticovo until 2029.
Number 3: Henlius gained approval in China for a bevacizumab biosimilar (Hanbeitai) and officials discussed combination therapy options with experimental therapy serplulimab and ophthalmology treatment.
Number 2: In a review, Sandoz researchers discussed lingering barriers that prevent insulin prices from falling to more affordable levels.
Number 1: Researchers reported findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.
To read all of these articles and more, visit centerforbiosimilars.com.
Switching From Originator Etanercept to Biosimilar Version Proves Safe, Effective in RA
September 5th 2024Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease activity and drug persistence compared with those who remained on the originator, indicating that nonmedical switching does not negatively impact treatment outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
